TrialBrain : a journal of neurology2025

Phase 2b program with sonlicromanol in patients with mitochondrial disease due to m.3243A>G mutation.

Jan Smeitink et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.